leadf
logo-loader
viewXPhyto Therapeutics Corp.

Xphyto Therapeutics provides update on their rapid COVID-19 screening test with 3a-Diagnostic

Xphyto Therapeutics (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive Vancouver with news the company is releasing new details about their rapid, disposable, point-of-care lateral flow screening test to detect COVID-19.

Rogers discusses what stage that testing is at and when he expected to be completed and brought to market.

Quick facts: XPhyto Therapeutics Corp.

Price: 2.69 CAD

CSE:XPHY
Market: CSE
Market Cap: $156.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Xphyto Therapeutics upgrades to OTCQB, moves closer to commercialization...

XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) CEO Hugh Rogers tells Proactive the firm is pleased to be able to trade its shares on the OTCQB to gain access to a wider investor base. Rogers says what's more, the development of its rapid saliva-based coronavirus (COVID-19) test is...

on 08/18/2020

2 min read